GlassScriptPhysician profile
Douglas Magenheim
NPI 1871574780
$9,744.46
in general payments reported to CMS, 2019-2025
49 companies · $2,061 in 2025
The $2,061 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2020: $1,170 · 2021: $1,032 · 2022: $1,268 · 2023: $1,640 · 2024: $1,770 · 2025: $2,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,469 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,469.15 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,620.41 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,619.14 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $998.82 | 2019-2025 | |
| Amgen INC. | $786.64 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $597.63 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $534.29 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $408.10 | 2022-2025 | |
| Lilly USA, LLC | $364.37 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Merck Sharp & Dohme LLC | $260.67 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Phathom Pharmaceuticals, INC. | $219.91 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $204.78 | 2019-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $188.79 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.59 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $145.33 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $131.89 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Magenheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.